Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431789 | 0.88 | GRM1 (0.36) | TP53LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5431688 | 0.87 | MEN1 (0.33) | TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL5446878 | 0.86 | BRD9 (0.39) | TP53LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5427442 | 0.85 | CTSS (0.35) | TP53MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL5794935 | 0.85 | MEN1 (0.40) | TP53MEN1KMT2AALDH1A1GPBAR1 | |
| SCHEMBL5429219 | 0.85 | ALDH1A2 (0.40) | TP53KMT2ANPSR1 | |
| SCHEMBL5438652 | 0.83 | CTSS (0.39) | TP53MEN1KMT2AALDH1A1CCR1 | |
| SCHEMBL5432024 | 0.83 | ALDH1A2 (0.34) | TP53LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5438500 | 0.82 | MAOA (0.40) | TP53LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5431788 | 0.82 | APLNR (0.40) | TP53LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | TP53 4137/4885LMNA 4257/4885MEN1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.